Table 2 Mortality rates and adverse events between daytime and nighttime administration before and after PSM.
Outcomes | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
Daytime n = 11,946 | Nighttime n = 13,491 | P Value | Daytime n = 8,704 | Nighttime n = 8,704 | P Value | |
Mortality rates at different time points (n, %) | ||||||
30-day | 1,798 (15.05%) | 3,003 (22.26%) | < 0.001 | 1,704 (19.58%) | 1,850 (21.25%) | 0.006 |
90-day | 2,408 (20.16%) | 3,955 (29.32%) | < 0.001 | 2,262 (25.99%) | 2,455 (28.21%) | < 0.001 |
180-day | 2,784 (23.30%) | 4,521 (33.51%) | < 0.001 | 2,594 (29.80%) | 2,842 (32.65%) | < 0.001 |
Adverse events associated with sepsis (n, %) | ||||||
SAE | 4,931 (41.28%) | 6,973 (51.69%) | < 0.001 | 3,970 (45.61%) | 4,436 (50.97%) | < 0.001 |
SIC | 5,613 (46.99%) | 5,687 (42.15%) | < 0.001 | 3,596 (41.31%) | 3,687 (42.36%) | 0.162 |
S-ALI | 1,688 (14.13%) | 3,225 (23.90%) | < 0.001 | 1,608 (18.47%) | 1,951 (22.41%) | < 0.001 |
AKI | 8,601 (72.00%) | 9,700 (71.90%) | 0.861 | 6,202 (71.25%) | 6,224 (71.51%) | 0.712 |
CRRT | 694 (5.81%) | 987 (7.32%) | < 0.001 | 624 (7.17%) | 597 (6.86%) | 0.423 |
